<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586831</url>
  </required_header>
  <id_info>
    <org_study_id>20150856</org_study_id>
    <nct_id>NCT02586831</nct_id>
  </id_info>
  <brief_title>Diabetes Islet Preservation Immune Treatment</brief_title>
  <acronym>DIPIT</acronym>
  <official_title>A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camillo Ricordi and Jay Skyler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diabetes Research Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether there is a difference in endogenous insulin secretion, measured as&#xD;
      stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance&#xD;
      test), at the 1 year visit, for study subjects receiving combinational therapy versus those&#xD;
      receiving placebo. The study will also examine the effect of the proposed treatments on&#xD;
      immunological outcomes, specifically proportion of regulatory T cells at the 1 year visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Simulated C-peptide AUC</measure>
    <time_frame>1 Year Visit</time_frame>
    <description>Endogenous insulin secretion as measured as stimulated C-peptide section Area Under the Curve (AUC) during a 4 hour mixed meal tolerance test (MMTT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of regulatory T cells</measure>
    <time_frame>1 Year Visit</time_frame>
    <description>As measured from blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c) levels</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Measure of glycemic control as evaluated by HbA1c levels from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Measure of glycemic control as evaluated by insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily plasma glucose levels</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Measure of glycemic control as evaluated by the mean daily plasma glucose levels from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of immune response adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Incidence of immune response adverse events as assessed by treating physician</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Hypoglycemia</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive Thymoglobulin, Aldesleukin, Adalimumab, and Exenatide over a period of 52 weeks.&#xD;
Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2&#xD;
Adalimumab (Humira®) will be administered at a dose of 50 mg every month, for 1 year&#xD;
Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®) will be administered 1 million IU/dose; 5 consecutive days (days 10-14), &amp; then every 2 weeks, for 52 weeks&#xD;
Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive the placebos for Thymoglobulin, Aldesleukin, Adalimumab, Exenatide, and Neulasta over a period of 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin (ATG)</intervention_name>
    <description>2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin 2</intervention_name>
    <description>1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Aldesleukin; IL-2 or Proleukin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>2 mg administered subcutaneously weekly for up to 52 weeks.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Bydureon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>50 mg administered subcutaneously once a month for 1 year.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>HUMIRA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ATG Placebo</intervention_name>
    <description>ATG placebo mimicking Thymoglobulin administered intravenously.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IL-2 Placebo</intervention_name>
    <description>IL-2 placebo mimicking Aldesleukin administered subcutaneously.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adalimumab Placebo</intervention_name>
    <description>Placebo mimicking Adalimumab administered subcutaneously.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exenatide Placebo</intervention_name>
    <description>Placebo mimicking Exenatide administered subcutaneously.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet all of the following criteria to be eligible to participate in this&#xD;
             study:&#xD;
&#xD;
               1. Subject must be able to understand and provide informed consent.&#xD;
&#xD;
               2. Males and females, 18-35 years of age.&#xD;
&#xD;
               3. New onset T1D for no longer than 120 days at the time of randomization.&#xD;
&#xD;
               4. Affected by T1D, according to ADA standard criteria, and confirmed by positivity&#xD;
                  of at least one T1D-associated autoantibody, to GAD65, IA-2, ZnT8, or insulin&#xD;
                  autoantibodies (if patient has been treated with insulin for less than 2 weeks).&#xD;
&#xD;
               5. Being on insulin therapy.&#xD;
&#xD;
               6. Stimulated C-peptide peak level &gt;0.2 nmol/L at the baseline 1 visit MMTT.&#xD;
&#xD;
               7. Female subjects of childbearing potential must have a negative pregnancy test&#xD;
                  upon study entry.&#xD;
&#xD;
               8. Female (and male) subjects with reproductive potential must agree to use two FDA&#xD;
                  approved methods of birth control for the entire duration of the study.&#xD;
&#xD;
               9. Adequate venous access to support study required blood draws.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Potential participants must not meet any of the following exclusion criteria:&#xD;
&#xD;
               1. Inability or unwillingness of a participant to give written informed consent or&#xD;
                  comply with study protocol.&#xD;
&#xD;
               2. BMI&gt;30 Kg/m2.&#xD;
&#xD;
               3. Contra-indications to ATG, GCSF, exenatide, etanercept and IL-2 (as per package&#xD;
                  insert, e.g., knowledge of hypersensitivity to drugs or its excipients).&#xD;
&#xD;
               4. Uncompensated heart failure, fluid overload, myocardial infarction or liver&#xD;
                  disease or severe impairment of a vital organ within the last 6 weeks before&#xD;
                  enrollment.&#xD;
&#xD;
               5. Any of the following laboratory findings: hemoglobin &lt;10.0 g/dL; leukocytes&#xD;
                  &lt;3,000/μL; neutrophils &lt;1,500/μL; lymphocytes &lt;800/μL; platelets &lt;100,000/μL.&#xD;
&#xD;
               6. Any sign or diagnosis of significant chronic active infection (e.g., hepatitis,&#xD;
                  tuberculosis, EBV, or CMV), or screening laboratory evidence consistent with a&#xD;
                  significant chronic active infection (such as positive for HIV, IGRA test for TB,&#xD;
                  or hepatitis B-C).&#xD;
&#xD;
               7. Ongoing acute infections, e.g., acute respiratory tract urinary tract, or&#xD;
                  gastrointestinal tract infections.&#xD;
&#xD;
               8. Ongoing or anticipated use of diabetes medications other than insulin.&#xD;
&#xD;
               9. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic&#xD;
                  control within prior 7 days of screening.&#xD;
&#xD;
              10. Current or prior use of immunomodulators or systemic steroids in the last 2&#xD;
                  months that could potentially affect diabetes or immunologic status.&#xD;
&#xD;
              11. Recent recipient of any licensed or investigational live attenuated vaccine(s)&#xD;
                  within 6 weeks of randomization.&#xD;
&#xD;
              12. Use of investigational drugs within 3 months of participation.&#xD;
&#xD;
              13. Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic&#xD;
                  agents, or previous therapy less than 3 months from randomization.&#xD;
&#xD;
              14. History or diagnosis of malignancy. Any history of gastroparesis or other severe&#xD;
                  gastrointestinal disease, pancreatitis, thyroid nodules or malignancy with the&#xD;
                  exception of a history of localized basal cell carcinoma.&#xD;
&#xD;
              15. Presence of an allograft.&#xD;
&#xD;
              16. AST, ALT or Alkaline Phosphatase &gt;2 times upper limit of normal or total&#xD;
                  bilirubin &gt;1.5 times upper limit of normal.&#xD;
&#xD;
              17. Current, diagnosed, mental illness or current, diagnosed or self-reported drug or&#xD;
                  alcohol abuse; or any situation that, in the opinion of the investigator, would&#xD;
                  interfere with the participant's ability to comply with study requirements.&#xD;
&#xD;
              18. Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both&#xD;
                  females and males of childbearing age to use a reliable and effective form of&#xD;
                  contraception, for the entire duration of the study.&#xD;
&#xD;
              19. Past or current medical problems, or findings from physical examination, or&#xD;
                  laboratory testing, that are not listed above which, in the opinion of the&#xD;
                  investigator, may pose additional risks from participation in the study, may&#xD;
                  interfere with the participant's ability to comply with study requirements or&#xD;
                  that may impact the quality or interpretation of the data obtained.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Institute, University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodolfo Alejandro, M.D.</last_name>
    <phone>(305) 243-5324</phone>
    <email>ralejand@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David A Baidal, M.D.</last_name>
    <phone>(305) 243-7740</phone>
    <email>dbaidal@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes Research Institute, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rodolfo Alejandro, M.D.</last_name>
      <phone>305-243-5324</phone>
      <email>ralejand@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>David A Baidal, M.D.</last_name>
      <phone>(305) 243-7740</phone>
      <email>dbaidal@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rodolfo Alejandro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Baidal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Skyler JS. Prevention and reversal of type 1 diabetes--past challenges and future opportunities. Diabetes Care. 2015 Jun;38(6):997-1007. doi: 10.2337/dc15-0349.</citation>
    <PMID>25998292</PMID>
  </reference>
  <reference>
    <citation>Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011 Jan;60(1):1-8. doi: 10.2337/db10-1114.</citation>
    <PMID>21193733</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Camillo Ricordi and Jay Skyler</investigator_full_name>
    <investigator_title>Professors, University of Miami Miller School of Medicine and Director/Deputy Director, Diabetes Research Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

